GLP-1 RAs STEP 1 (2021) : Semaglutide 2.4 ./ 14.9% 68 2.4% (Wilding et al., 2021, NEJM) SURMOUNT-1 (2022) : Tirzepatide (GLP-1/GIP dual agonist) 15 ./ 20.9% (Jastreboff et al., 2022, NEJM) GLP-1 HbA1c () 2 (Hypoglycemia) Glucose-dependent LEADER (liraglutide) SUSTAIN-6 (semaglutide) 2024 FDA Semaglutide (Wegovy) FLOW (2024) semaglutide (MASLD/NAFLD) GLP-1 RAs GLP-1
11 Figure 2: The likelihood of patients being diagnosed with depression after a GLP-1 prescription compared to those on a non-GLP-1 medication 11 Initial studies on the risk of suicide in individuals taking GLP-1s indicate that these drugs may increase suicidal thoughts and ideation
Its worth noting that these positive effects were only seen in patients taking long-acting GLP-1 receptor agonists (more commonly prescribed) and not in those using short-acting agents
Ascorbic acid, as vitamin C is scientifically called, supports both the cellular immune response (defense) and the humoral immune response (release of antibodies)
Traditional Healthcare Route Schedule an appointment with your primary care doctor, endocrinologist, or weight management specialist
Psoriatic arthritis and metabolic syndrome: Is there a role for disease modifying anti-rheumatic drugs